OpenAlex
PricingAboutJobs
Log inGet started
Work

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

HTML

Year: 2005
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-04-2658
Authors: Jeffrey W. Clark, Joseph P. Eder, David Ryan, Chetan Lathia, Heinz-Josef Lenz
Institutions: Massachusetts General Hospital, University of Southern California, USC Norris Comprehensive Cancer Center
Language: English

Topic: Colorectal Cancer Treatments and Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: sorafenib, multikinase inhibitor, Raf kinase inhibitor, maximum tolerated dose, dose-limiting toxicity, rash, hypertension, pharmacokinetics, solid tumors, refractory cancer, tumor angiogenesis, tumor cell proliferation, MAPK signaling, phospho-ERK, tumor response
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2166271687
FWCI: 16.37
Cites: 17
Cited by: 367
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms